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Abstract
Background: Human amnion epithelial cells (hAECs) are clonogenic and have been proposed to reduce inflammatory-
induced tissue injury. Perturbation of the immune response is implicated in the pathogenesis of perinatal brain injury;
modulating this response could thus be a novel therapy for treating or preventing such injury. The immunomodulatory
properties of hAECs have been shown in other animal models, but a detailed investigation of the effects on brain
immune cells following injury has not been undertaken. Here, we investigate the effects of hAECs on microglia, the first
immune responders to injury within the brain.
Methods: We generated a mouse model combining neonatal inflammation and perinatal hyperoxia, both of which are
risk factors associated with perinatal brain injury. On embryonic day 16 we administered lipopolysaccharide (LPS), or saline
(control), intra-amniotically to C57Bl/6 J mouse pups. On postnatal day (P)0, LPS pups were placed in hyperoxia (65%
oxygen) and control pups in normoxia for 14 days. Pups were given either hAECs or saline intravenously on P4.
Results: At P14, relative to controls, LPS and hyperoxia pups had reduced body weight, increased density of apoptotic
cells (TUNEL) in the cortex, striatum and white matter, astrocytes (GFAP) in the white matter and activated microglia
(CD68) in the cortex and striatum, but no change in total microglia density (Iba1). hAEC administration rescued the
decreased body weight and reduced apoptosis and astrocyte areal coverage in the white matter, but increased the
density of total and activated microglia. We then stimulated primary microglia (CD45lowCD11b+) with LPS for 24 h,
followed by co-culture with hAEC conditioned medium for 48 h. hAEC conditioned medium increased microglial
phagocytic activity, decreased microglia apoptosis and decreased M1 activation markers (CD86). Stimulating hAECs for
24 h with LPS did not alter release of cytokines known to modulate microglia activity.
Conclusions: These data demonstrate that hAECs can directly immunomodulate brain microglia, probably via release of
trophic factors. This observation offers promise that hAECs may afford therapeutic utility in the management of perinatal
brain injury.
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Background
Preterm birth is a major, independent, risk factor for neuro-
developmental impairment because of the infant’s immatur-
ity. Most babies born very preterm (<32 weeks) require
ventilator support to manage respiratory distress syndrome,
and although intervention strategies have greatly improved
the survival of these infants, the incidence of bronchopul-
monary dysplasia and associated neurodevelopmental prob-
lems has not changed dramatically [1, 2]. The pathogenesis
of the underlying brain injury is complex, but is thought to
involve both inflammation and ischaemia leading to down-
stream oxidative stress and subsequent neuronal and
axonal death [3]. Importantly, the innate immune response
plays a critical role in the inflammatory sequelae to hyp-
oxic–ischaemic injury in the brain and therefore in the
extent of any subsequent functional loss [4]. The glial
response to injury is involved in the pathogenesis of mul-
tiple central nervous system (CNS) disorders [5], and
microglial activation has been linked to oxidative
stress-induced neurotrauma [6]. Microglia are the resi-
dent immune cells within the CNS that are the first
responders to injury [7]. It is increasingly appreciated
that modulation of microglial activation can confer
neuroprotection in diverse forms of injury or inflamma-
tion [8–10], suggesting that microglia may be a novel
therapeutic target for brain injury, including injury
during early brain development [11, 12].
Cell therapies have recently attracted much interest as
potential treatments for some of the key complications of
preterm birth [13–15]. For example, human amnion epi-
thelial cells (hAECs) appear particularly promising for pre-
term lung injury [13, 16, 17] and amniotic fluid cells for
necrotizing enterocolitis [18]. With regard to perinatal
brain injury, hAECs have also been shown to reduce lipo-
polysaccharide (LPS)-induced fetal brain inflammation
and subsequent injury [19]. While hAECs express early
neural markers [20] and are able to differentiate into neu-
rons, astrocytes and oligodendrocytes in vitro [21], their
reparative effects are thought to be primarily exerted via
modulation of the host immune response to injury [22].
While no studies to date have examined whether hAECs
can modify microglial function in brain injury, the repara-
tive actions of hAECs within the lung are macrophage
dependent [23, 24].
There are a myriad of animal models for preterm brain
injury, developed both to improve the understanding of
the different pathways to injury and to identify new
therapeutic targets [25–27]. Rodent models are the most
common, due to the extensive amount of literature cor-
relating rodent anatomical and functional development
to the appropriate stage in humans [28]. These studies
have shown that the stage of brain development of a
human infant at birth is roughly equivalent to the neuro-
development of a rodent at postnatal day (P)12–13 [11].
Thus, studies of pre-weaning rodents (first 2 postnatal
weeks) are thought to appropriately mimic stages of hu-
man brain development that occur late in utero, or ex
utero in the case of severely preterm birth [29]. It is also
thought that a two-hit model of brain injury, combining
prenatal inflammatory insult and secondary oxidative
stress, may best reflect the pathogenesis of common
human preterm brain injury [30]. Inflammation and oxi-
dative stress are stressors that together increase the
probability of developing white matter injury and associ-
ated respiratory disease, both of which are common in
very preterm infants [31]. Further, infants exposed to ex-
cessively high oxygen saturation levels are at increased
risk of complications such as retinopathy of prematurity
and bronchopulmonary dysplasia [32]. Despite this, the
association of brain injury with combined intrauterine
infection and hyperoxia is not well understood. To this
end we have used a mouse model of neonatal brain
injury that utilizes both intra-amniotic administration of
LPS (inflammation) and perinatal chronic hyperoxia.
LPS is a widely used insult that induces an innate
inflammatory response [33] mimicking fetal or neonatal
infection that is a major risk factor for perinatal brain injury
[34]. In our model of combined intra-amniotic LPS and
perinatal chronic hyperoxia, we aimed to characterize in-
jury within brain regions that are vulnerable to hyperoxia-
induced and/or inflammation-induced damage in preterm
infants such as the cerebral white matter, cerebral cortex
and striatum [6, 35]. We then sought to assess the effect, if
any, of hAECs in mitigating these changes with a particular
focus on microglial modulation.
Methods
Experimental groups
C57Bl6/J mice were allocated randomly into four ex-
perimental groups as follows: control animals were
given intra-amniotic saline at embryonic day 16 (E16)
and born into normoxia (21% O2); and hyperoxia
groups were given intra-amniotic LPS at E16, and then
placed in hyperoxia (65% O2) immediately after birth.
Mice (both control and LPS + hyperoxia animals) were
then administered either saline or hAECs on P4.
hAEC isolation
Placentae were collected from women with uncomplicated
pregnancies undergoing elective caesarean sections at
term. Collection and isolation of hAECs was performed as
described previously [36]. The mean gestational age of
consenting women was 38 weeks. Cells were then cryo-
preserved using standard methods at 5 × 106 cells/ml.
Only isolates with >85% post-thaw cell viability, >90%
EpCAM-positive cells and <1% CD90/105-positive cells
were used in this study. Freshly thawed hAECs were used
for all experiments described in this manuscript (i.e. P1).
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Surgery
Induction of the intra-amniotic inflammation was per-
formed as described previously [25]. Briefly, on E16 preg-
nant C57Bl/6 J mice were anaesthetized with isofluorane
and the amniotic sacs were exteriorized by hysterotomy
through a midline abdominal incision. The uterine horn
was exposed and LPS from Escherichia coli (1 μg in 50 μl
saline, 055:B5; Sigma, St. Louis, MO, USA) or 50 μl saline
was administered to each amniotic sac. To do so, we used
an automated microinjection system (IM 300; Narishige,
Tokyo, Japan) with bevelled glass micropipettes pulled
using a P-1000 micropipette puller (Sutter Instruments,
CA, USA) connected to the microinjection system. The
micropipette was physically advanced towards the uterine
wall and into the amniotic cavity, and LPS or saline was
administered. The micropipettes were then retracted
physically, a new amniotic sac positioned and the proced-
ure repeated. After the injections were completed, the
uterine horn was placed back into the abdominal cavity,
the laparotomy closed and the mother recovered. The
overall procedure took less than 30 min per dam, from in-
cision to closure. Pups were then allowed to deliver natur-
ally at term (E21). Control (saline administered) pups
were placed into normoxia (21% O2) chambers and pups
administered intra-amniotic LPS were placed into hyper-
oxia (65% O2) chambers, for 14 days consecutively. We
did not experience any mortality in our experimental
groups.
hAEC treatment
At P4 mice were briefly (<60 min) removed from their
hyperoxic or normoxic chamber to be administered ei-
ther normal saline (10 μl) or hAECs (100,000 cells in
10 μl saline) intravenously via the superficial temporal
vein, using the automated microinjection system as per
the intra-amniotic injections. Pups were then placed
back into their respective chambers until P14.
Perfusion and tissue preparation
At P14 all pups (control, n = 9; LPS + hyperoxia, n = 7;
LPS + hyperoxia + hAECs, n = 6) were killed via keta-
mine–xylazine overdose (200 μl of 100 mg/ml ketamine
10 mg/ml xylazine per 8 g body weight) and transcardially
perfused with saline. After clearance of circulating blood,
4% paraformaldehyde (PFA) in 0.1 M phosphate buffer
(pH 7.4) was perfused for a further 5 min. Brain tissue was
then post-fixed in 4% PFA for 24 h at 4 °C. The cerebral
hemispheres were embedded in paraffin and 5-μm-thick
serial coronal sections were cut from the anterior pole of
the lateral ventricle to the hippocampus. Every eighth sec-
tion was stained using haematoxylin and eosin for orienta-
tion purposes and analysis of gross morphological changes
or stained immunohistochemically.
Immunohistochemistry
Sections from control (n = 9), LPS + hyperoxia (n = 6)
and LPS + hyperoxia + hAEC (n = 7) pups were exposed
to heat-induced epitope retrieval using citrate buffer
(pH 6) and blocked in 2% (w/v) bovine serum albumin
in phosphate-buffered saline for 1 h and primary anti-
body applied overnight at 4 °C in a humid chamber.
Immunohistochemistry was performed on paraffin-
embedded sections to detect microglia (ionized calcium-
binding adaptor molecule 1 (Iba1), 1:1000, 019-19741;
Wako Pure Chemical Industries, Osaka, Japan), activated
microglia (CD68, 1:100, MCA1957; ABD Serotec, Ox-
ford, UK) and astrocytes (glial fibrillary acidic protein
(GFAP), 1:1000, M7240; DAKO, CA, USA), as described
previously [37]. hAEC cell tracking was performed using
anti-human HLA-G (HLA-G clone 87G, 1:100, ALX-
805-719-c100; Enzo Lifesciences, Australia). Biotinylated
secondary antibodies (1:200) were applied for 1 h at
room temperature in a humid chamber and reacted with
the VectaStain Elite avidin–biotin complex kit (1:200;
Vector Laboratories, CA, USA) using 3,3′-diaminobenzi-
dine as the chromagen. Following counterstaining with
haematoxylin, slides were coverslipped with DPX
(Sigma-Aldrich, MO, USA). Omission of the primary
antibody resulted in no specific staining. For each anti-
body, all sections were stained simultaneously to ensure
uniform conditions for subsequent analysis.
TUNEL assay
Sections were labelled using the DeadEnd Colorimetric
terminal transferase nick end-labelling (TUNEL) system
(Promega, Madison, WI, USA) to identify apoptotic and
necrotic cell death [38], as per the manufacturer’s direc-
tions. Additional sections were exposed to DNAse I
(Roche Molecular Biochemicals) and incubated at 37 °C
for 30 min (positive control) or incubated without ter-
minal transferase (negative control).
Imaging and quantitative analysis
Images were scanned on an Aperio Scanscope XT
(Aperio Technologies, CA, USA) for image analysis
using ImageScope software (Aperio Technologies) for
individual cell counts, and the ImageJ Fiji software pack-
age (NIH Image, MD, USA) for calculation of positive
staining area. The observer (BL) was blinded to experi-
mental groups to prevent bias. Analysis was done using
three replicates per animal and a mean calculated per
animal. A mean of means was then determined for each
experimental group. For the hAEC tracking experiments,
slides were counterstained with DAPI 1:5000 for 15 min,
and images were scanned on a Nikon C1 Confocal laser-
scanning microscope.
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Cell density of GFAP-positive, Iba1-positive, CD68-positive
and TUNEL-positive cells
GFAP-positive, Iba1-positive, CD68-positive and TUNEL-
positive cells were counted in 5-μm-thick coronal sections
(separated by 40 μm, three sections per animal). In the
striatum (Iba1, CD68), analysis was performed in five ran-
dom fields of view (objective: 40×; field size 0.04 mm2). In
the motor-somatosensory cortex (Iba1, CD68), counts
were performed in one field divided into three bins corre-
sponding to specific cortical layers (bin 1: layers I/II, bin 2:
layers III/IV, bin 3: layer V). In white matter tracts (GFAP,
Iba1, CD68), counts were in random fields of view (object-
ive: 40×; field size 0.04 mm2) in the corpus callosum (two
fields of view), cingulum (two fields of view) and external
capsule (three fields of view). TUNEL-positive cells were
counted within the entire cross-sectional area of the stri-
atum, cerebral cortex and subcortical white matter. The
area of each region or field of view was determined to
calculate areal density (cells/mm2) of GFAP-positive, Iba1-
positive, CD68-positive and TUNEL-positive cells.
Percentage area occupied by GFAP-positive cells
In each of the groups (three sections per animal; 40 μm
apart) the proportion of brain regions occupied by GFAP-
positive astrocytes was assessed (objective: 40×; field size
0.04 mm2) throughout the striatum (five random fields of
view), motor-somatosensory cortex (five fields of view),
corpus callosum, cingulum (two fields of view) and exter-
nal capsule (three fields of view). The proportion of stain-
ing in each section was totalled and averaged, and was
expressed as a percentage of the brain region.
Real-time polymerase chain reaction for human ALU
sequences
Brains from LPS + hyperoxia pups (n = 2) and LPS +
hyperoxia + hAEC pups (n = 3) were collected as
already detailed. Then 10 mg of brain tissue were
weighed out and RNA extracted using the PureLink
Genomic DNA Mini Kit (Invitrogen). Real-time poly-
merase chain reaction (PCR) was performed with the
use of the Applied Biosystems Power SYBR Green
PCR Master Mix and the Rotorgene RG-3000 (Cor-
bett Research, Australia). A 100 ng sample of total
DNA was used in the PCR assay under the following
cycling conditions: 95 °C for 10 min, then 35 cycles
of 95 °C for 15 sec, 68 °C for 30 sec and 72 °C for
30 sec. The ALU primer sequence used was forward
5′-CATGGTGAAACCCCGTCTCTA-3′ and reverse
5′-GCCTCAGCCTCCCGAGTAG-3′. The PCR prod-
ucts were resolved by electrophoresis in 2% agarose
gels, and the bands were visualized under UV light.
DNA from 1 × 106 hAECs were used as a positive
control (+ve).
hAEC cell tracking by immunofluorescence
Cell tracking of hAECs was performed using anti-human
HLA-G (HLA-G clone 87G, 1:100, ALX-805-719-c100;
Enzo Lifesciences) on 10-μm-thick brain sections from
LPS + hyperoxia treated (n = 3) and untreated (n = 3) ani-
mals. Secondary antibody (1:200) was applied for 1 h at
room temperature in a humid chamber.
Primary microglia isolation using magnetic isolation
Primary microglia cell cultures were isolated using the
EasySep® Mouse CD11b Positive Selection Kit (STEM-
CELL Technologies, Vancouver, Canada) as per the man-
ufacturer's instructions. Briefly, brains were isolated
from healthy, untreated CX3CR1GFP/+ P14 mice (mini-
mum n = 3 per experimental group) and the meningeal
layer removed and washed in ice-cold Dulbecco's modi-
fied Eagle medium (DMEM) supplemented with high
glucose (DMEM/F12-High Glucose; Life Technologies,
Australia) and 1% penicillin–streptomycin (PS; Life
Technologies, Australia). Brains were then mechanically
dissociated using fine scissors and triturated using a pip-
ette. The subsequent single-cell suspension was passed
through a 40-μm cell strainer. Cells were then pelleted
and suspended in 1 ml of DMEM-F12 to obtain a final
concentration of no more than 1.0 × 108 cells/ml. The
cell suspension was then transferred to a Falcon™ 5-ml
polystyrene round-bottom tube (BD Biosciences, San
Jose, CA, USA). Then 50 μl of rat serum was added to
the sample, followed by incubation with EasySep® Selec-
tion Cocktail for 5 min. The tube was then placed into
an EasyEights™ magnet for 10 min, and the supernatant
carefully collected by pipette and discarded. This mag-
netic separation process was repeated three times (1 ×
10 min, 2 × 5 min) to enhance the purity of the collected
cells, and the sample allowed to recover overnight before
proceeding with in-vitro studies. Culture purity was veri-
fied by flow cytometry from a subset of animals used (n
= 5) with the microglia purity (CD45lowCd11b+) deter-
mined as >88%. Experimental groups consisted of micro-
glia cultured in control media alone (DMEM/F12-High
Glucose with L-glutamine, FBS and antibiotics), hAEC-
conditioned media, LPS and LPS with subsequent
culture in hAEC-conditioned media. Microglia were
exposed to an inflammatory stimulus by culturing in
media containing 1 μg/ml LPS (L2630; Sigma-Aldrich)
for 48 h prior to experimental treatments.
Collection of hAEC-conditioned media
Freshly thawed hAECs (0.5 × 106) were seeded into a
T175 flask (353028; BD Falcon®, Bedford MA, USA) with
20 ml DMEM/F12 (11320033; Invitrogen) supplemented
with 10% heat-inactivated FBS (16000-036; Invitrogen)
and penicillin–streptomycin (15070-063; Invitrogen).
hAECs were cultured at 37 °C in 5% CO2 for 4 days.
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The conditioned medium was then collected and filtered
through a 0.2-μm pore filter (16532; Sartorius Stedim
Biotech, Goettingen, Germany) prior to use.
Flow cytometric analysis
Staining protocol for M1/M2 phenotyping
Primary microglia (n = 3 animals for each group) were
incubated with an Fc-receptor blocker (553141; BD
Pharmingen) for 15 min on ice and stained with the
following antibodies: CD45-V450 (1:100, 560541; BD
Biosciences, North Ryde, NSW, Australia), Cd11b-PE
(1:100, 12-0112; eBioscience, San Diego, CA, USA),
CD86-phycoerythrin cyanine 7 (PE Cy-7, 1:200, 560501;
BD Bioscience) and CD206-Alexa Fluor 647 (1:200,
12310; Australian Biosearch, Karrinyup, WA, Australia).
All samples were run in duplicate, and flow cytometric
data were collected on a BD FACS Canto II Analyzer
(BD Biosciences) and analysed using FlowJo cytometric
analysis software (Tree Star, Ashland, OR, USA).
MTS assay
Microglia viability and proliferation was assessed using
the Promega MTS assay (G5421; Promega), according to
the manufacturer’s instructions. Briefly, 5 × 103 microglia
were plated into each well of a 96-well plate (BD Fal-
con). Primary microglia were stimulated with LPS with
or without hAEC-conditioned medium (n = 3 animals
for each group). For each treatment and time-point,
20 μl of MTS solution was added, and microglia were
incubated for 4 h. Optical density was measured at
490 nm with the SpectraMax i3 Spectrophotometer
(Molecular Devices, CA, USA). All samples were run in
triplicate and analysed using the built-in SoftMax Pro
software suite.
Phagocytic assay
The phagocytic activity of microglia was determined
using a pHrodo assay as described previously [24].
Microglia were plated in 24-well flat-bottom culture
plates (BD Falcon, Australia) at a density of 1.5 × 105
cells per well overnight at 37 °C and 5% CO2. Microglia
were then stimulated with or without LPS and hAEC-
conditioned medium (n = 3 animals for each group).
pHrodo® Red E. coli BioParticles® (10 μg/ml, 10025; Life
Technologies, Australia) were added to each well and
phagocytic activity analysed by fluorescence-activated
cell sorting (FACS) after 30-min incubation at 37 °C.
Negative controls were pre-chilled in ice to inhibit mem-
brane movement. All samples were run in duplicate, and
flow cytometric data were collected on a BD FACS
Canto II Analyzer (BD Biosciences) and analysed using
FlowJo cytometric analysis software (Tree Star).
Apoptosis assay
Primary microglia were plated at a density of 1 × 105
cells per well in a 24-well plate (BD Falcon) and stimu-
lated with LPS with or without hAEC-conditioned
medium (n = 5 animals for each group). Microglia were
removed by aspiration and stained using the Annexin
V:PE Apoptosis Detection Kit (BD Biosciences) accord-
ing to the manufacturer’ s instructions. Propidium iodide
(PI) was used to stain dead cells. Early-stage and late-
stage apoptotic microglia were identified by use of the
BD FACS Canto II Analyzer (BD Biosciences) and ana-
lysed using FlowJo 8.7 software (Tree Star).
Cytokine assays
hAECs were thawed and seeded in T175 flasks overnight
at 37 °C and 5% CO2. The following morning, cells were
lifted using 0.05% trypsin and seeded at a density of
0.5 × 106 cells/well in a 24-well plate (BD Falcon). Cells
were stimulated with LPS (100 ng/ml) for 24 h and
supernatant collected and spun down briefly to remove
particulates (500 × g for 5 min). Levels of IL-6
(SKU0029; ELISAkit, Melbourne, VIC, Australia), IL-10
(SKU0007; ELISAkit), IL-37 (ELH-1L1F7; RayBioTech,
GA, USA) and IL-1Ra (ab100565; abcam, Cambridge,
UK) were measured in duplicate following the manufac-
turers’ instructions and quantified on a SpectraMax i3
Spectrophotometer (Molecular Devices).
Statistics
Data were expressed as mean ± standard error of the
mean (SEM). Differences between groups were analysed
by an unpaired one-way analysis of variance unless
otherwise stated. For differences assessed by one-way
ANOVA, Newman–Keuls post-hoc correction was ap-
plied where appropriate to correct for multiple compari-
sons. All analysis was done using GraphPad Prism
(GraphPad Software Inc, CA, USA). Data were consid-
ered significant when p < 0.05.
Results
There were no significant differences between saline
alone animals and saline + hAEC-treated pups raised
in normoxia for any of the physiological or immuno-
histochemical outcomes. Therefore, only outcomes
relating to LPS + hyperoxia pups with (n = 7) or with-
out hAECs (n = 6) are compared with saline alone
(control) animals (n = 9).
Body and brain weights
At P14 the mean body weight of LPS + hyperoxia ani-
mals was significantly reduced compared with controls
(Fig. 1a, p < 0.001; controls, n = 9; LPS + hyperoxia, n = 6;
LPS + hyperoxia + hAECs, n = 7), an effect normalized
by hAEC administration (p < 0.05 vs LPS + hyperoxia,
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p > 0.05 vs control). There was no difference in brain
weight between groups (Fig. 1b). However, the brain to
body weight ratio was significantly increased in LPS +
hyperoxia animals compared with both controls and LPS
+ hyperoxia + hAEC animals (Fig. 1c, p < 0.001 and p <
0.01, respectively).
Gross structural analysis of the brain
Qualitative assessment of key brain structures in haema-
toxylin and eosin-stained slides revealed no evidence of
gross morphological abnormalities (e.g. lesions, infarcts,
necrosis, hydrocephalus or areas of pallor) in any experi-
mental groups.
hAECs in the brain
HLA-G immunoreactivity was observed in the cerebral
cortex, white matter and striatum (Fig. 2a). We also
detected the presence of human DNA within the brains,
as shown by amplification of human ALU repeats by
real-time PCR (Fig. 2b; LPS + hyperoxia + hAEC animals,
n = 3; LPS + hyperoxia alone, n = 2).
Apoptosis
We performed the TUNEL assay to identify cells in late
apoptotic stages exhibiting extensive DNA degradation
in the striatum, white matter and cortex, because these
are regions known to be susceptible to damage in pre-
term brain injury [39]. Cells that were TUNEL-positive
were stained brown by the diaminobenzidine (DAB)
chromogen and the majority of these cells displayed
nuclear condensation, a well-identified morphological
characteristic of cells undergoing apoptosis [40]. There
was an increase in the density of TUNEL-positive cells
in the striatum (Fig. 3a, p < 0.01; controls, n = 9; LPS
+ hyperoxia, n = 6; LPS + hyperoxia + hAECs, n = 7),
subcortical white matter (Fig. 3b, p < 0.001) and
motor-somatosensory cortex (Fig. 3c, p < 0.001) in
LPS + hyperoxia animals compared with controls. Ad-
ministration of hAECs to LPS + hyperoxia animals
reduced TUNEL-positive cell density back to near
control levels in all brain regions in LPS + hyperoxia ani-
mals (Fig. 3a–c; striatum, p < 0.05; white matter, p < 0.01;
cortex, p < 0.001), as illustrated by representative images
taken from the striatum of control (Fig. 3d), LPS +
hyperoxia (Fig. 3e) and LPS + hyperoxia + hAEC (Fig. 3f )
animals.
Astrocytes
The density of GFAP-positive cells in the corpus callo-
sum (Fig. 4a), cingulum (Fig. 4b) and external capsule
(Fig. 4c) was increased in LPS + hyperoxia pups com-
pared with controls (p < 0.05; controls, n = 9; LPS +
hyperoxia, n = 6; LPS + hyperoxia + hAECs, n = 7), an
effect not mitigated by hAEC administration. We then
assessed the proportion of the brain region occupied by
GFAP immunostaining to take into account an effect on
Fig. 1 Brain and body weights in LPS and hyperoxia-treated animals, and effects of hAEC administration. a Body weights were significantly re-
duced by LPS + hyperoxia, with hAEC treatment reversing this change. b Brain weights were unchanged in the hyperoxia groups. c Brain to body
weight ratio was increased in LPS + hyperoxia animals compared with controls, but was restored to control levels after hAEC treatment. *p < 0.05;
**p < 0.01; †††LPS + hyperoxia versus control, p < 0.001. hAEC human amnion epithelial cell, LPS lipopolysaccharide
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astroglial hypertrophy. There was an increase in the area
coverage of GFAP immunoreactivity in the corpus callo-
sum (Fig. 4d, p < 0.05), cingulum (Fig. 4e, p < 0.05) and ex-
ternal capsule (Fig. 4f, p < 0.001) in LPS + hyperoxia
animals compared with controls. Treatment with hAECs
mitigated this increase in all regions (corpus callosum and
cingulum, p < 0.05; external capsule, p < 0.01; Fig. 4d–f ),
as shown by representative images of the external capsule
of control (Fig. 4g), LPS + hyperoxia (Fig. 4h) and LPS +
hyperoxia + hAEC (Fig. 4i) animals.
Microglia/macrophages
We assessed the density of microglia/macrophages in the
striatum, cortex and white matter, as shown by the repre-
sentative figures (Fig. 5a–c). In the striatum, there was no
difference in the areal density of Iba1-positive cells in LPS
+ hyperoxia animals compared with controls. Administra-
tion of hAECs significantly increased Iba1-positive cell
density (Fig. 5d, p < 0.01; controls, n = 9; LPS + hyperoxia,
n = 6; LPS + hyperoxia + hAECs, n = 7).
In the motor-somatosensory cortex, Iba1-positive cell
density was not affected by LPS and hyperoxia (Fig. 5e-g).
As in the striatum, administration of hAECs increased
Iba1-positive cell density in bins 1 and 2, corresponding to
cortical layers I/II and layers III/IV (Fig. 5e, f, p < 0.05).
The density of Iba1-positive cells in the corpus callo-
sum in LPS + hyperoxia animals was not different from
that in controls (Fig. 5h, p > 0.05), but was significantly
decreased in the cingulum (Fig. 5i, p < 0.05) and the ex-
ternal capsule (Fig. 5j, p < 0.05). As for the striatum and
cortex, hAEC administration to LPS + hyperoxia pups
significantly increased the density of Iba1-positive cells
in the corpus callosum (p < 0.001), cingulum (p < 0.05)
and external capsule (p < 0.05).
We next quantified the density of activated microglia/
macrophages using the marker CD68 as shown by repre-
sentative images (Fig. 6a-c), because Iba1 labels both
resting and activated states [41, 42]. In the striatum, the
density of CD68-positive activated microglia/macro-
phages was significantly increased in LPS + hyperoxia
animals compared with controls (Fig. 6d, p < 0.001; con-
trols, n = 9; LPS + hyperoxia, n = 6; LPS + hyperoxia +
hAECs, n = 7) and further increased in LPS + hyperoxia
+ hAEC animals (Fig. 6d, p < 0.05). We observed a simi-
lar effect across the three groups of animals in the cere-
bral cortex (Fig. 6e, f ), with an increase in the density of
CD68-positive cells in LPS + hyperoxia pups compared
with controls (bins 2 and 3 only; p < 0.01 for both) and a
further increase in hAEC-treated animals across all three
regions (p < 0.01 for all groups). We observed no signifi-
cant differences in CD68-positive cell density in the corpus
Fig. 2 Tracking of hAECs within the brain. a Representative staining of DAPI (nuclear stain, blue) and HLA-G (green). HLA-G immunoreactive fragments
were detected in cerebral cortex of 14-day-old hAEC-treated animals. Scale bar = 50 μm for main image, 3 μm for inset. b Gel electrophoresis of PCR
products amplified from DNA extracted from the brains of treated and untreated LPS + hyperoxia animals. From left to right: Promega 100 bp DNA
ladder, hAECs (positive control), hAEC-treated animals, untreated animals (Colour figure online). hAEC human amnion epithelial cell
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callosum, cingulum and external capsule in LPS + hyper-
oxia animals compared with controls (p > 0.05). However,
compared with both control and LPS + hyperoxia animals,
LPS + hyperoxia + hAEC pups had a significant increase
in CD68-positive cell density in the corpus callosum
(Fig. 6h–j; p < 0.05 vs control, p < 0.01 vs LPS + hyperoxia).
In-vitro assessment of microglial function after hAEC
co-culture
In light of our observations regarding increased density of
total and activated microglia/macrophages following
hAEC administration, we explored whether hAEC-
conditioned medium could alter microglial function in
vitro. To do this, we ran a series of in-vitro assays using
primary microglia isolated from brains of healthy 14-day-
old CX3CR1GFP/+ mice, which express GFP in all mono-
nuclear phagocytes, and whose expression in the brain is
restricted to microglia [43]. We then co-cultured these
microglia with hAEC-conditioned medium, compared
with controls treated with ultra-culture medium alone.
Following 24 h of stimulation with LPS, co-culture of
primary microglia with hAEC-conditioned medium
significantly decreased the amount of CD86-positive M1-
subtype microglia, as determined by FACS analysis (Fig. 7a;
30.1 ± 0.95% vs 27.9 ± 0.66% total cells, n = 3 each group,
p = 0.0173, Student’s t test). hAEC-conditioned media had
no effect on microglia proliferation, as assessed by the
MTS assay, at 24, 48 or 72 h (Fig. 7b; n = 3 each group),
but increased microglia phagocytic activity (Fig. 7c, d;
0.76 ± 0.58% vs 5.88 ± 0.60% total cells, n = 4 each group,
p = 0.0328, Student’s t test).
We next assessed microglia apoptosis after 24 h of
LPS stimulation, with or without hAEC-conditioned
medium for 24 h (Fig. 8). We found that hAEC-
conditioned medium significantly increased the per-
centage of live microglia (CX3CR1+) compared with
ultra-culture only controls (Fig. 8a; 5.1 ± 0.27% vs 8.7 ±
0.39% total cells, n = 5 each group, p = 0.0022, Student’s
t test). This was accompanied with a decrease in per-
centage of apoptotic microglia (Fig. 8b; 0.46 ± 0.087% vs
0.10 ± 0.05% total cells, n = 5 each group, p = 0.0038,
Student’s t test).
Finally, we sought to determine whether the modulatory
effect of hAECs on microglia was a result of the release of
pro-inflammatory and anti-inflammatory cytokines known
to have modulatory or polarizing roles on microglia and
macrophages. Following 24-h stimulation with LPS, we
found no significant differences in levels of IL-6, IL-10, IL-
Fig. 3 Density of terminal deoxynucleotidyl transferase 2′-deoxyuridine, 5′-triphosphate nick end labelling (TUNEL) apoptotic cells in the brain. Density
of TUNEL cells was increased in the striatum (a), white matter tracts (b) and cerebral cortex (c) of LPS + hyperoxia animals. Representative figures showing
no TUNEL-positive cells in a control animal (d) and increased TUNEL-positive cells (as indicated by black arrows) exhibiting nuclear condensation in an LPS
+ hyperoxia animal (e), which was reduced by hAECs (f). *p< 0.05; **p< 0.01; ***p< 0.001; ††LPS + hyperoxia versus control, p< 0.01; †††LPS + hyperoxia
versus control, p< 0.001. Scale bar (d–f) = 30 μm. hAEC human amnion epithelial cell, LPS lipopolysaccharide
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37 or IL-1Ra released by hAECs relative to unstimulated
controls (Fig. 9; control, n = 10; LPS stimulation, n = 7;
Student’s t test).
Discussion
Using a mouse model of perinatal brain injury, induced by
intrauterine inflammation and perinatal hyperoxia, we have
shown that, when administered neonatally, hAECs are
effective at reducing injury severity as evidenced by de-
creased apoptosis and astrogliosis. However, somewhat
surprisingly, the administration of hAECs was associated
with an increase in both microglial density and activation
in the cerebral cortex, striatum and subcortical white mat-
ter. Exploring this further, we showed that co-culture of
LPS-stimulated microglia with hAEC-conditioned medium
reduced the percentage of CD86+ microglia, and increased
microglial phagocytic activity. While hAEC-conditioned
medium did not affect microglia proliferation, it did in-
crease the percentage of live, LPS-challenged microglia
after 48 h, with a corresponding decrease in percentage of
apoptotic microglia compared with cells cultured in con-
trol medium alone. These observations suggest that hAECs
may be an effective neuroprotective cell therapy acting via
immunomodulation of microglia.
A two-hit model to mimic neonatal brain injury
Infection and respiratory compromise are thought to be
common and important antecedents of subsequent brain
Fig. 4 Assessment of astrocytosis in the cerebral white matter tracts. Density of GFAP-IR astrocytes in the corpus callosum (a), cingulum
(b) and external capsule (c) was increased in LPS + hyperoxia animals compared with controls. hAEC treatment did not alter the density
of GFAP-IR astrocytes in all regions (a–c). Percentage area covered by GFAP staining was increased in the corpus callosum (d), cingulum
(e) and external capsule (f) in LPS + hyperoxia animals compared with controls. Interestingly, hAEC treatment reduced the percentage area
covered by GFAP staining in all regions (d–f). Representative figures showing GFAP staining in the external capsule of control (g), LPS + hyperoxia (h)
and LPS + hyperoxia + hAEC (i) animals. *p < 0.05; **p < 0.01; †LPS + hyperoxia versus control, p < 0.05; †††LPS + hyperoxia versus control, p < 0.001.
Scale bar (g–i) = 150 μm. GFAP glial fibrillary acidic protein, hAEC human amnion epithelial cell, LPS lipopolysaccharide
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injury in extreme preterm infants, regardless of whether
the injury arises before or shortly after birth [44, 45]. Pre-
vious work by others indicated an intermediate “tolerance”
window about 24–48 h after LPS administration during
which mice were actually protected from hypoxia–ischae-
mic brain injury [46, 47]. After this “tolerance” window,
brains are primed from LPS pre-treatment and neural in-
jury is increased instead. In a mouse model of HI and
combined LPS, the degree of brain injury was more severe
with LPS pre-treatment 72 h before HI than with just HI
alone [48]. In our mouse model we sought to mimic this
“two-hit” injury and thus administered LPS intra-
amniotically at E16, 5 days before exposure to hyperoxia
and thus outside this tolerance window, confirming that
the combined insult induces subtle brain injury. The ef-
fects of hyperoxia in perinatal brain injury have not been
researched extensively, with most studies applying hypoxia
instead [3, 49]. However there is growing recognition that
ventilation strategies which do not account for transient
reduction in oxygen requirements, or prolonged continu-
ous positive airway pressure, can increase oxidative stress
in vital organs such as the lung and brains, and can result
in the development of preterm infant complications such
as perinatal brain injury [2]. Ventilation-induced injuries
are further complicated by preterm infants already experi-
encing a several-fold increase in arterial oxygen concen-
tration after birth, which could exacerbate injury. In fact,
avoiding unnecessarily high oxygen saturation targets has
Fig. 5 Assessment of the microglial response in the striatum. Representative images illustrating Iba1 immunoreactivity in the cingulum of control (a),
LPS + hyperoxia (b) and LPS + hyperoxia + hAEC (c) animals. d Density of Iba1-positive cells in the striatum was not different between control and LPS +
hyperoxia animals but was increased with administration of hAECs. e–g Assessment of the microglial response in the cerebral cortex. Density of Iba1-
positive cells was not different between control and LPS + hyperoxia animals in all three bins, but was increased with administration of hAECs in bin 1 (e)
and bin 2 (f). h–j Assessment of the microglial response in the white matter tracts. Density of Iba1-positive cells was not different between control and LPS
+ hyperoxia animals in the corpus callosum (h) but was reduced in the cingulum (i) and external capsule (j).*p< 0.05; **p< 0.01; †LPS + hyperoxia versus
control, p< 0.05. Scale bar (a–c) = 200 μm. CC corpus callosum, Cg cingulum, hAEC human amnion epithelial cell, LPS lipopolysaccharide
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been associated previously with improved outcomes spe-
cifically in preterm infants [50]. Given that hyperoxia has
been shown to result in delayed white matter development
and long-term white matter deficiency in a rat model [51],
there is an urgent need to better understand the impact of
hyperoxia and how we can prevent the development of
long-term complications.
Here we report that LPS + hyperoxia exposure caused
apoptosis in the striatum, cerebral white matter and
motor-somatosensory cortex at P14. This supports pre-
vious reports using similar models [12, 26, 27] showing
apoptotic injury with perinatal inflammation and
hyperoxia-induced brain injury in mice. Astrogliosis was
also evident 14 days after onset of perinatal hyperoxia,
and nearly 20 days after the initial prenatal inflammatory
insult. Astrogliosis occurs following brain injury [52]
and is commonly associated with neural damage induced
by cerebral hypoxia [53] and disruption of the fragile
Fig. 6 Assessment of microglial activation in the striatum. Representative images showing CD68+ activated microglia/macrophages in the
striatum of control (a), LPS + hyperoxia (b) and LPS + hyperoxia + hAEC (c) animals. LPS and hyperoxia significantly increased the density of CD68+
activated microglia/macrophages, and this was further increased in hAEC-treated animals (d). e–g Assessment of microglia/macrophage activation in the
cerebral cortex. Density of CD68+ cells was not different between control and LPS + hyperoxia animals in bin 1 (e), but was increased in bin
2 (f) and bin 3 (g). Administration of hAECs to LPS + hyperoxia animals increased the density of CD68+ cells activated in all three bins (e–g).
h–j Assessment of CD68 staining in the cerebral white matter tracts. Density of CD68+ cells was not different between control and LPS +
hyperoxia animals in the corpus callosum (h), cingulum (i) or external capsule (j); administration of hAECs increased the density of CD68+
cells in the corpus callosum (h). *p < 0.05; **p < 0.01; ††LPS + hyperoxia versus control, p < 0.01; †††LPS + hyperoxia versus control, p < 0.001.
Scale bar (a–c) = 25 μm. Black arrows, CD68+ cells.hAEC human amnion epithelial cell, LPS lipopolysaccharide
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astrocyte–neuron relationship, resulting in reduction
of dendritic arborization and increased synaptic loss
[54, 55]. Increased astrocyte processes, or hypertrophy,
as well as increased astrocyte cell numbers, or hyperplasia,
are hallmarks of reactive astrogliosis seen in models of
CNS injury or neurodegenerative disease, although there
is clear evidence that astrocyte hypertrophy can occur in-
dependent of hyperplasia and is arguably more important
in the pathology of CNS trauma [56]. Our observation of
increased area coverage of GFAP reflects up-regulation of
this intermediate filament protein in response to injury,
and thus long-term transcriptional changes due to the
continued stress [57]. This activates pathways leading to
disturbed ion homeostasis, energy metabolism and glu-
tamate release resulting in neuronal apoptosis. The per-
sistence of astrogliosis could have implications for brain
function, because astrocytes are both neurosupportive and
neurodegenerative [58, 59]. This highlights the potential
importance of proper management of assisted ventilation
of preterm babies.
Microglial proliferation and/or activation are typical
markers of inflammation and injury in the brain [7, 9, 60].
Studies utilizing similar animal models of either neonatal
LPS administration [61] or chronic hyperoxia after birth
[31, 62], albeit at much higher O2 concentrations (80%
and 85% respectively), have reported increases in micro-
glia density and activation. Here we report that at P14
there was an increase in the proportion of CD68-positive
activated microglia/macrophages but no difference in the
total density of Iba1-positive cells in animals that received
prenatal LPS in combination with chronic perinatal hyper-
oxia. This heterogeneity in the microglial response to brain
injury is interesting; however, it is likely that the differences
across studies are attributable to both the length of time as
well as window of onset of injury. In line with this reason-
ing, previous studies administering intraperitoneal LPS in-
jections to pregnant rats at E13.5 reported no change in
microglia density at 3 and 6 weeks of age respectively [63].
Another possibility is that we have missed the peak time-
point for microglia expansion. Previous studies have
reported that the peak microglial response to primary
inflammatory-induced injury was approximately 5–14 days
later [64], and between 1 and 2 weeks for secondary injury
[63], which corroborates the lack of increase in microglia
density at P14. The long-term functional implications of
increased microglial activation in our model remain
Fig. 7 Effects of hAEC-conditioned medium treatment on primary microglia isolated from P14 animals, relative to controls treated with ultra-culture
medium alone. a Percentage of microglia expressing the M1 marker CD86 and M2 marker CD206; 24-h exposure to hAEC-conditioned medium
significantly reduced the percentage of CD86 expressing microglia. b Soluble factors from hAECs do not affect microglia proliferation after LPS
stimulation at 24, 48 or 72 h. c Representative FACS plots illustrating the marked increase in pHrodo+ cells after 24-h hAEC co-culture. d After
a 24-h co-culture of primary microglia with hAECs, the number of pHrodo+ cells increased significantly. *p < 0.05, **p < 0.01, Student’s t test.
hAEC human amnion epithelial cell, CM conditioned medium
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unknown, but other studies have shown that sustained
microglial overactivation can induce demyelination [63]
and neurodegeneration [65]. A recent study proposed that
this neurotoxicity may be due to epigenetic changes in
microglia after injury that persist into adulthood [66].
Taken together, these studies suggest that chronic inflam-
mation at a critical window of development is sufficient to
cause long-term impairment and thus swift intervention is
required.
Amnion cells as a therapy for brain injury
The reparative therapeutic potential of hAECs was
highlighted by the recognition that they possessed stem
cell-like characteristics [20, 36]. hAECs have been
assessed in a multitude of other experimental animal
models including bronchopulmonary dysplasia [17], can-
cer [67] and multiple sclerosis [68]. In a previous study
using a hyperoxia-induced model of lung injury, hAECs
significantly reduced tissue fibrosis and inflammatory
markers when administered via intraperitoneal injection
[17]. However, to date there has been only one study ex-
ploring their reparative effects in perinatal brain injury
[19]. In that study, intrauterine LPS was used to mimic
chorioamnionitis and subsequent brain injury in a fetal
sheep model. The findings reported in the current study
are broadly in line with the previous study in that hAEC
administration in our mouse model of perinatal brain
injury was also associated with less cell death and astro-
gliosis. Specifically, we observed reduced astroglial
hypertrophy, as reflected by a reduction in GFAP area
coverage, after hAEC administration. Reduction in astro-
cyte area coverage after injury typically marks a return
Fig. 8 Soluble factors from hAEC protect microglia after LPS stimulation. a Following 24 h of LPS stimulation, 48-h exposure to hAEC-conditioned
medium significantly increased the percentage of live microglia and reduced the percentage of apoptotic microglia. b Representative FACS plots
demonstrating the shift of microglia into Q4 (Annexin-V+ PI–). Q1 necrotic cells, Q2 late apoptotic or dead cells, Q3 live cells, Q4 early apoptotic
cells. *p < 0.05, Student’s t test. hAEC human amnion epithelial cell, CM conditioned medium
Fig. 9 Release of cytokines from hAECs following 24-h LPS stimulation.
Stimulation with LPS did not significantly alter the release of
known microglia-modulating cytokines IL-6, IL-37, IL-10 or IL-1Ra.
LPS lipopolysaccharide
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to a non-reactive state, signalling a return to homeosta-
sis [69]. However, in contrast to the previous report, we
found that hAEC administration, intriguingly, increased
microgliosis and activation in the striatum and white
matter rather than decreasing it [19].
The reason for this apparent difference in microglial
number and activation states between this study and
previous findings is not clear. It is possible that it relates
to the timing of cell administration relative to the insult.
In the study by Yawno et al. [19], the hAECs were
administered at the same time as LPS, almost in a pre-
ventative manner. Here, we administered hAECs after
the combinatorial infection and hyperoxia had been
allowed to establish for 4 days, which is a more likely
scenario in clinic. Similar experiments using hAECs to
prevent acute lung injury have also shown that adminis-
tration immediately after the insult prevents macrophage
migration into the lung [24, 70], whereas inflammation
was not suppressed when hAECs were given 7 days after
the insult [71]. Further assessment of the timing of
hAEC administration and their effectiveness in prevent-
ing or repairing brain injury is certainly merited.
Here, we observed HLA-G immunoreactivity within
the white matter, striatum and cortex of the hAEC-
treated LPS + hyperoxia animals, 10 days after hAECs
were administered. We also detected the presence of hu-
man ALU repeat sequences within the brain, suggesting
the presence of human DNA. Whilst the HLA-G stain-
ing co-localized with DAPI, given the shape and size of
the stain, it is likely that we are detecting amnion cell
fragments that have entered the brain. This corroborates
previous work using CFSE labelling showing that hAECs
are able to cross the blood–brain barrier after being
administered via intravenous injection in both a sheep
model of brain injury [19] and a similar hyperoxia-
induced mouse model of lung injury [17]. While we are
unable to confirm whether hAECs enter the brain fully
intact or after fragmentation, our work and other studies
have demonstrated that the effects of hAECs are prob-
ably due to trophic factors released by hAECs rather
than direct engraftment [24, 72]. Specifically, we demon-
strated previously that hAEC-conditioned medium is
sufficient to modulate the activity of lung macrophages,
without the need for cell-to-cell contact with amnion
cells [22]. In this model, we noted increased CD68 (or
ED-1) expression after hAEC administration, which
occurs during progressive activation of microglia away from
their quiescent resting state, along with other markers such
as vimentin [73, 74]. This is associated with increased
phagocytosis as well as increased proliferation and expres-
sion of major histocompatibility complexes which are usu-
ally upregulated during disease resolution. Using in-vitro
co-culture assays we thus sought to reproduce these find-
ings in primary brain microglia. We observed significant
modulation of microglia activation and survival, with
hAEC-conditioned medium causing a reduction in CD86-
positive microglia, increased phagocytosis and increased
survival after LPS stimulation. The polarization and activa-
tion of microglia to either an M1 or M2 subtype in vivo is
not biphasic, but rather a complex, constantly-evolving
process [7]. Activation states will thus be highly dependent
on the time-point at which the assay was performed. Given
that the CD68 histological data were collected from brain
tissue 10 days after hAEC administration and the M1/M2
polarization assay only 72 h after LPS stimulation, it is
unsurprising that there was a disparity in the CD68 and
CD86 findings (both are typically used as markers of the
M1 subtype [75]). Nonetheless, we were able to conclude
that hAEC-conditioned medium could affect microglia
polarization in the acute phase.
The hAEC-induced changes in phagocyte polarization
states have been reported previously. In a bleomycin-
induced acute lung injury model we reported that hAECs
can mediate macrophage polarization away from the pro-
inflammatory M1 phenotype (CD86+) to the pro-reparative
M2 phenotype (CD206+) [24]. It is well described in the lit-
erature that M2 microglia play critical roles in wound heal-
ing and repair [76], and are associated with reduced
inflammation and increased phagocytic activity [77]. It is
likely that the induction of phagocytosis is an important
element of how hAECs facilitate injury repair, whether in
the lung or brain. During injury, microglial activation and
subsequent phagocytosis are widely regarded as critical for
disease resolution [78] as a result of increased clearance of
toxic debris and production of neurite growth-inhibiting
compounds, both of which are vital for neuronal recircuitry
and repair [79]. Further, activated microglia have been pro-
posed to “phagoptose” live but stressed neurons that have
been exposed to noxious stimuli, such as reactive oxygen
species [80], to induce them to express “eat-me” signals,
such as phosphatidylserine and calreticulin [81]. In our co-
culture assays, we also observed increased microglia sur-
vival after inflammatory insult and subsequent treatment
with hAEC-conditioned medium. Taken together, it is at-
tractive to propose that hAECs are protecting microglia
from inflammation-induced injury. This allows for sus-
tained activation and phagocytosis of toxic apoptotic debris
or phagoptosis of stressed-but-viable neurons, which in
other neurodegenerative disorders has been shown to result
in resolution of pathology.
Beyond these “clearance activities”, activated microglia
are also thought to play a number of other roles in brain
injury repair [82]. For example, they are able to drive
oligodendrocyte differentiation during re-myelination
[83], protect neurons during oxygen and glucose deple-
tion in stroke models [84] and promote neurite out-
growth and arborization in a spinal cord injury model
[85]. Our observations in this current study suggest that
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hAECs may be able to promote these functions via
modulation of host microglia.
Cytokines are a key mediator of microglia function
and activity [81]. As such, we assessed cytokine release
from hAECs after LPS stimulation in vitro to elucidate
potential glial modulatory pathways. We showed no dif-
ferences in the levels of the LPS-inducible cytokine IL-6
[86] and the anti-inflammatory cytokines IL-10, IL-37
and IL-1Ra [87] after 24 h of LPS stimulation. IL-10 and
IL-37 have been shown in the literature to polarize
microglia towards the alternatively activated M2 subtype,
which is pro-reparative [77, 88], as well as to induce
microglia phagocytosis [89]. However, combined with
our in-vivo data showing no effect of hAEC treatment
for uninjured animals, the release of cytokines in an
inflammatory environment is suggested not to be the
major pathway by which hAECs modulate microglia. In-
deed, previous studies suggest that hAECs mediate their
reparative and neurotrophic properties via release of
growth factors such as brain-derived neurotrophic factor
and neurotrophin-3 [90]. Further research should
attempt to elucidate the precise factors and pathways ac-
tivated by hAECs in modulating microglia function and
survival.
Cell therapies have been a particular focus for treating
cerebral palsy in the past 5 years. Clinicaltrials.gov lists
seven ongoing and completed trials that have utilized
autologous stem cells derived from bone marrow or cord
blood. Currently, our research group is conducting a
first-in-human phase 1b safety trial for hAEC adminis-
tration to infants with severe bronchopulmonary dyspla-
sia (ACTRN12614000174684), and have been funded
and granted approval to assess hAECs in adult liver
cirrhosis (ACTRN12616000437460p). To progress the
translation of hAECs into the clinic further, future stud-
ies should assess the long-term neuropathological and
behavioural effects of hAECs in other preclinical models
of perinatal brain injury. The aetiology of cerebral palsy
is multifactorial, and thus showing therapeutic merit in
multiple preclinical models of cerebral palsy encom-
passing different pathogenic pathways [49], as well as
improvement in long-term outcomes, would greatly
support the transition of hAECs to the clinic.
Conclusions
We have generated a mouse model of perinatal brain injury
combining prenatal LPS with chronic perinatal hyperoxia.
We observed an increase in apoptosis in the striatum, cere-
bral white matter and cortex, as well as astrogliosis in the
white matter tracts in 14-day-old animals. Administration
of hAECs at P4 was effective at significantly reducing apop-
tosis and astrogliosis and was accompanied by microgliosis
in the cortex, white matter and striatum. We also showed
that in-vitro hAEC-conditioned medium can exert direct
immunomodulatory effects on microglia. We demon-
strate here that factors released from hAECs reduced
M1 activation and increased phagocytic activity, con-
sistent with the reduced apoptosis in LPS + hyperoxia +
hAEC mice. Treatment with hAEC-conditioned medium
also increased survival and reduced apoptosis of microglia
after LPS stimulation, although it had no effect on micro-
glia proliferation. While previous studies have assessed the
therapeutic potential of hAECs in the brain, this is the first
evidence that hAECs are able to modulate microglia
within the brain, a property that does not appear to be
mediated by release of cytokines by hAECs. These data
suggest that hAECs have therapeutic utility in neonatal
brain injury and the findings of this study add to the
mounting evidence supporting their clinical use.
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